DVM

Pro Plan Veterinary Diets Launches Veterinary Support Mission

Retrieved on: 
Tuesday, January 16, 2024
Well, Patient, Research, Animal, Health, Veterinarian, Face, Workload, Pet, AVMF, DVM, Organization, REACH

ST. LOUIS, Jan. 16, 2024 /PRNewswire/ -- Purina Pro Plan Veterinary Diets is helping veterinarians fulfill their call to care with the launch of the Pro Plan Veterinary Support Mission, a new initiative created to help remove barriers veterinarians often face in practice. As its first act, the brand donated $1 million to the American Veterinary Medical Foundation (AVMF) REACH program, which offers grants to veterinarians providing immediate pet care when owners experience financial hardship.

Key Points: 
  • ST. LOUIS, Jan. 16, 2024 /PRNewswire/ -- Purina Pro Plan Veterinary Diets is helping veterinarians fulfill their call to care with the launch of the Pro Plan Veterinary Support Mission, a new initiative created to help remove barriers veterinarians often face in practice.
  • Through the Pro Plan Veterinary Support Mission, Dr. Harris noted, the company has committed to making a meaningful difference by supporting organizations that help veterinarians navigate these difficulties, allowing them to answer their call to care.
  • The Pro Plan Veterinary Support Mission embodies the company's long-term commitment to meeting the personal and professional needs of the veterinary profession, Dr. Harris concluded.
  • Veterinarians can visit www.ProPlanVetSupport.com to learn more about the Pro Plan Veterinary Support Mission and to see if they qualify for a grant under the AVMF REACH program.

2024 Feather in Her Cap and High Flyer Award Winners Named for Outstanding Achievements in Animal Health Industry

Retrieved on: 
Tuesday, January 16, 2024
Philanthropy, Health, Consumer, Women, Foundation, Veterinary, Animal Health, Woman, Osteoarthritis, Therapy, Frunevetmab, Multimedia, Female, Intellectual disability, University, Engagement, Mentorship, Dog, Pharmaceutics, Elanco, Veteran, Cat, DVM, Boehringer Ingelheim, ELAN, Doctor of Philosophy, Veterinary medicine, Highflyer, Feather, Marketing, Formulation, Inclusion, Education, Management

The Feather in Her Cap Association, Inc. and 300 industry leaders honored 11 women for their outstanding career achievements in Animal Health at the seventh annual Feather in Her Cap awards ceremony.

Key Points: 
  • The Feather in Her Cap Association, Inc. and 300 industry leaders honored 11 women for their outstanding career achievements in Animal Health at the seventh annual Feather in Her Cap awards ceremony.
  • Andrea J. Gonzales Ph.D., vice president of Global Companion Animal Therapeutics at Zoetis, Inc., (NYSE: ZTS) was awarded the 2024 Feather in Her Cap award and Katharina Bohnenblust Ph.D., senior director, head of Formulation Development at Elanco Animal Health (NYSE: ELAN) was this year’s recipient of the 2024 High Flyer award.
  • Each year, the Feather in Her Cap award winner chooses an animal-related non-profit organization to receive a $5,000 donation.
  • The nomination process will reopen in Q3 of 2024 to celebrate more outstanding women in Animal Health in 2025.

Dvm360® elevates veterinary education and networking: Fetch conference in new location, Nashville, TN

Retrieved on: 
Friday, January 12, 2024
Research, Multimedia, Music City Center, Friends, Faculty, MBA, DVM, Education, CE, Growth

For decades, Fetch conferences have been a cornerstone of the veterinary community, offering unparalleled CE experiences.

Key Points: 
  • For decades, Fetch conferences have been a cornerstone of the veterinary community, offering unparalleled CE experiences.
  • Their innovative approach to veterinary education is designed to address current industry challenges and propel the veterinary community toward a future of continual growth.
  • “This strategic move signifies a significant stride in our commitment to fulfilling promises and advancing excellence in veterinary education.”
    As an innovator in veterinary education, dvm360 has tailored its events to serve today’s veterinary professionals.
  • “We are proud to usher in a new chapter of growth and collaboration within the veterinary community,” said John Hydrusko, vice president of dvm360 and Fetch.

Antech launches breakthrough in-hospital innovation, Nu.Q® Canine Cancer Test

Retrieved on: 
Friday, January 12, 2024
Element, Hemangiosarcoma, VMX, Volition, EDTA, Dog, Science, Pet, Cancer, Lymphoma, Plasma, Disease, DVM, Transport, Nucleosome, Telehealth, Veterinarian

ORLANDO, Fla., Jan. 12, 2024 /PRNewswire/ -- Antech, the veterinary diagnostics company focused on helping veterinary professionals predict, diagnose and monitor wellness and disease, today announced it will launch the breakthrough in-hospital Nu.Q® Canine Cancer Test at this year's annual VMX meeting.

Key Points: 
  • ORLANDO, Fla., Jan. 12, 2024 /PRNewswire/ -- Antech, the veterinary diagnostics company focused on helping veterinary professionals predict, diagnose and monitor wellness and disease, today announced it will launch the breakthrough in-hospital Nu.Q® Canine Cancer Test at this year's annual VMX meeting.
  • Nu.Q ® is a breakthrough technology that measures circulating nucleosomes, supporting earlier cancer detection in some of the most prevalent types of canine cancers.
  • To learn more about the in-hospital Nu.Q ®, visit booth 1522 at VMX 2024 or speak to your local Antech representative.
  • The Nu.Q® Canine Cancer Test is supplied to Antech's Heska affiliate under license by Belgian Volition SRL.

IDEXX Announces Revolutionary Slide-Free Cellular Analyzer, IDEXX inVue Dx™ Transforming In-Clinic Workflows

Retrieved on: 
Friday, January 12, 2024
Patient, IDXX, Idexx Laboratories, Ear, Hematology, Seamless, Laboratory, Workflow, Ecosystem, Cell, DVM, Diagnosis, Veterinarian, Blood, Medical device

WESTBROOK, Maine, Jan. 12, 2024 /PRNewswire/ -- IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, announces the launch of the IDEXX inVue Dx™ Cellular Analyzer, a first-of-its-kind slide-free cellular analyzer to detect the most common cytologic changes found in ear and blood samples. With deep AI learning models trained by IDEXX board-certified pathologists, the in-clinic analyzer provides practitioners with reference-laboratory quality results in 10 minutes. Unlike traditional slide methods, the IDEXX inVue Dx analyzer examines cells in their natural state, providing multidimensional images of sample findings and enabling diagnostic insights like never before.

Key Points: 
  • With deep AI learning models trained by IDEXX board-certified pathologists, the in-clinic analyzer provides practitioners with reference-laboratory quality results in 10 minutes.
  • Unlike traditional slide methods, the IDEXX inVue Dx analyzer examines cells in their natural state, providing multidimensional images of sample findings and enabling diagnostic insights like never before.
  • The IDEXX inVue Dx platform's capabilities will grow over time, with expansion to screening lumps and bumps with fine needle aspirate samples planned next.
  • "Veterinary professionals are exceedingly busy and are eager for ways to increase capacity," said Jay Mazelsky, President and Chief Executive Officer of IDEXX.

COVETRUS® EXPANDS ROLE AND RESPONSIBILITIES FOR DR. LINK WELBORN, CHIEF VETERINARY OFFICER

Retrieved on: 
Thursday, January 11, 2024
VCPR, Patient, Veterinary medicine, Hospital, Animal, Health, Policy, American Animal Hospital Association, Federal, Telehealth, AAHA, Practice management, DVM, Human, Physical examination, Veterinarian

PORTLAND, Maine, Jan. 11, 2024 /PRNewswire/ -- Covetrus® , a global leader in animal-health technology and services, today announced that Link Welborn , DVM, DABVP, the company's Chief Veterinary Officer, will assume an expanded role and additional responsibilities in 2024.

Key Points: 
  • PORTLAND, Maine, Jan. 11, 2024 /PRNewswire/ -- Covetrus® , a global leader in animal-health technology and services, today announced that Link Welborn , DVM, DABVP, the company's Chief Veterinary Officer, will assume an expanded role and additional responsibilities in 2024.
  • He will continue as CEO of Veterinary Study Groups , the umbrella organization for the more than 60 Veterinary Management Groups .
  • "We thank Link for his willingness to take on these additional responsibilities."
  • In his role as external spokesperson, Dr. Welborn will serve as Covetrus' leading voice for veterinary health-related topics and their impact on the veterinary industry, such as telemedicine and VCPR (veterinary-client-patient relationship).

Fear Free Proudly Pairs Up with bSerene™ Pet Pheromone Products

Retrieved on: 
Thursday, January 11, 2024
Tail, Pheromone, Partnership, Science, Dog, Pet, Anxiety, Lip, Shivering, Cat, Socialization, Rigidity, Fear, DVM, Common, MAP, Free, DAP, Marketing, Yawn, SVP, Bottled water

DENVER, Jan. 11, 2024 /PRNewswire-PRWeb/ -- Fear Free® is excited to announce its partnership with science-guided pet pheromone brand bSerene™, which has come on board as a corporate program member.

Key Points: 
  • Fear Free is excited to announce its partnership with science-guided pet pheromone brand bSerene™, which has come on board as a corporate program member.
  • DENVER, Jan. 11, 2024 /PRNewswire-PRWeb/ -- Fear Free® is excited to announce its partnership with science-guided pet pheromone brand bSerene™, which has come on board as a corporate program member.
  • First and foremost, both companies are filled with pet lovers who want to reduce fear, anxiety, and stress in pets," - Randy Valpy, CEO of Fear Free.
  • First and foremost, both companies are filled with pet lovers who want to reduce fear, anxiety, and stress in pets," says Randy Valpy, CEO of Fear Free.

AI and Drug Development: Keeping it Real with Pharma, Upcoming Webinar Hosted by Xtalks

Retrieved on: 
Thursday, January 11, 2024
Doctor of Philosophy, Drug discovery, Research, Automation, Intelligence, Drug development, AI, Scientist, DVM, Common, Medical device

TORONTO, ON, Jan. 11, 2024 /PRNewswire-PRWeb/ -- Discover an informative webinar delving into industry insights about artificial intelligence's (AI) impact on drug development automation. We've all heard the hype around artificial intelligence, especially its application for drug discovery and development. In some corners, it's coming to replace jobs. In others, it's going to revolutionize life science and the pharmaceutical industry. But what do drug developers really think about using AI? Are established companies ready to incorporate AI for success and competitive advantage? If so, how are they doing it today?

Key Points: 
  • In this free webinar, gain insights into real-world applications for the use of AI in pharmaceutical R&D.
  • TORONTO, ON, Jan. 11, 2024 /PRNewswire-PRWeb/ -- Discover an informative webinar delving into industry insights about artificial intelligence's (AI) impact on drug development automation.
  • We've all heard the hype around artificial intelligence, especially its application for drug discovery and development.
  • Join this webinar to learn innovative insights into drug development automation and build new capabilities to remain a leading pharmaceutical producer.

Elevating Veterinary Care: Walkin' Pets Launches Vet Exclusive Line at VMX 2024, Experience Live Demonstrations and Exclusive Offers at Booth #2131

Retrieved on: 
Wednesday, January 10, 2024
Swelling, Patient, Leg, VMX, Gait, Injury, Pet, DBE, Articulation (music), Orange County Convention Center, Proprioception, Movement, Bandage, DVM, Walkin, Motion, Hock, Veterinary medicine

ORLANDO, Fla., Jan. 10, 2024 /PRNewswire/ -- Walkin' Pets announces a new vet exclusive product line with mobility solutions designed for pet professionals.

Key Points: 
  • ORLANDO, Fla., Jan. 10, 2024 /PRNewswire/ -- Walkin' Pets announces a new vet exclusive product line with mobility solutions designed for pet professionals.
  • The Walkin' Pets new veterinary exclusive line gives veterinary professionals the tools they need to offer their patients the highest level of care with Walkin' Pets most advanced and trusted products designed specifically to complement their patients' treatment plans.
  • Join Walkin' Pets at VMX 2024 Booth #2131 for live demonstrations, expert consultations, and exclusive offers that underscore the brand's commitment to transforming the lives of pets and their families.
  • For more information about Walkin' Pets' Vet Exclusive Line, visit https://vets.handicappedpets.com/ or experience Walkin' Pets firsthand at VMX Booth #2131.

Gallant Therapeutics Raises Over $15 Million in Series A Funding to Advance Pipeline of "Off-the-Shelf" Stem Cell Therapies for Pets

Retrieved on: 
Monday, January 8, 2024
Pet, Cat, FDA, Conditional sentence, Health, Disease, Microsoft Exchange Server, SAN, Therapy, Dog, Chronic kidney disease, DVM, FCGS, Stem cell, OA, Veterinary medicine, Growth, Gallant, CKD, Pharmaceutical industry

SAN DIEGO, Jan. 08, 2024 (GLOBE NEWSWIRE) -- Gallant Therapeutics , an animal health biotechnology company pioneering off-the-shelf stem cell therapies for pets, today announced the successful completion of its Series A financing, securing over $15 million.

Key Points: 
  • SAN DIEGO, Jan. 08, 2024 (GLOBE NEWSWIRE) -- Gallant Therapeutics , an animal health biotechnology company pioneering off-the-shelf stem cell therapies for pets, today announced the successful completion of its Series A financing, securing over $15 million.
  • The successful funding round will enable Gallant to accelerate the development of its pipeline of potentially first-in-class allogeneic stem cell therapeutics, focusing on achieving conditional FDA approval for its leading therapeutic candidate targeting FCGS, a deadly disease with a high unmet medical need.
  • “We have made unprecedented progress this past year, hitting significant clinical, regulatory, and manufacturing milestones,” said Linda Black, DVM, Ph.D., CEO of Gallant Therapeutics.
  • This series A funding represents a crucial step toward Gallant’s vision of bringing "off-the-shelf" stem cell therapies to veterinary clinics worldwide.